Predictors of Poor Visual Outcome in Myelin Oligodendrocyte Glycoprotein-Related Optic Neuritis


Tags Neuro
Journal Ophthalmology
Status 審查完成
校稿者 蕭靜熹 醫師

Ophthalmology Volume 130, Number 9, September 2023



該研究旨在確定髓鞘細胞蛋白相關視神經炎(Myelin Oligodendrocyte Glycoprotein-Related Optic Neuritis ,MOG-ON)患者中視覺不良結果的比例,以及與這些結果相關的因素。該研究是一項回顧性的病歷審查,涉及48名患者,其中有45名符合納入標準。主要結果指標是不良的視覺結果,其定義為受影響眼的最終中央視力(VA)超過0.4 logMAR,或在視野測試中平均偏差(MD)小於-5.0 dB。



English Abstract

The study aims to identify the proportion of patients with poor visual outcomes in Myelin Oligodendrocyte Glycoprotein-Related Optic Neuritis (MOG-ON) and the factors associated with these outcomes. The study is a retrospective chart review involving 48 patients, of which 45 met the inclusion criteria. The primary outcome measure was poor visual outcomes, defined as a final central visual acuity (VA) of more than 0.4 logMAR or mean deviation (MD) of less than -5.0 dB on perimetry in the affected eye.

The study found that 42.2% of patients had poor visual outcomes, which challenges the current belief that most MOG-ON patients achieve good visual outcomes. Early treatment with corticosteroids was found to be associated with better visual outcomes. The average time from symptom onset to treatment initiation was significantly shorter in those with good outcomes compared to those with poor outcomes. No significant difference was found in the type of corticosteroid administration (oral vs. intravenous) or neuroradiologic features in predicting visual outcomes.

The study concludes that almost half of the patients with MOG-ON had poor visual outcomes, emphasizing the importance of early treatment with corticosteroids. The study also found that oral corticosteroids were non-inferior to intravenous administration for achieving good visual outcomes. No neuroradiologic feature was predictive of visual outcomes.